



*Second Quarter
Ended October 31, 2005*

CORPORATE OFFICE:

202, 279 Midpark Way SE

Calgary, Alberta, T2X 1M2 Canada

Phone: (403) 254-9252 Fax: (403) 256-8495 Email: info@resverlogix.com

www.resverlogix.com

TRADING SYMBOL:

TSX: RVX

December 12, 2005

MANAGEMENT'S DISCUSSION AND ANALYSIS

This management's discussion and analysis of operations and financial position should be read in conjunction with Resverlogix Corp.'s ("Resverlogix" or the "Company") October 31st, 2005 Quarterly Financial Statements. The financial statements have been prepared by management in accordance with Canadian Generally Accepted Accounting Principles (GAAP).

OVERVIEW

Resverlogix is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Resverlogix's principal technology is NEXVAS™ Apolipoprotein AI (ApoAI) Program, a natural physiological approach to increase the serum levels of ApoAI, the primary component of high density lipoprotein (HDL), the "good cholesterol," to treat cardiovascular diseases. The Company's research and discoveries within NEXVAS has lead to expansion of cardiovascular disease applications to address the inflammation and Drug Eluting Stent (DES) markets. Resverlogix's application within the DES market is now referred to as ReVas™. The TGF-β Shield™ Program utilizes an adoptive immunotherapy approach to target cancers and fibrotic diseases. Resverlogix is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases.

The Company is focused on the primary stages of drug development, leading to Investigational New Drug (IND) application and early stage clinical studies. This strategy will avoid the significant costs and unknown results of the final phases of the drug development process (late stage clinical trials) by either licensing or selling its technology. Hence, a major portion of the biotech investment risk should be eliminated.

Shares of Resverlogix trade on the TSX under the symbol, RVX.

HIGHLIGHTS

During the year, the Company announced a Request For Proposal (RFP) process with seven leading global life science organizations for an exclusive standstill agreement regarding its NEXVAS technology in cardiovascular disease (CVD). Resverlogix is continuing to have discussions with these pharmaceutical firms and will not disqualify any candidate until the Company can conclude the formal agreements. Resverlogix's goal remains to establish an early partnership arrangement, via a stand still agreement, with the ideal candidate to accelerate the sale of technology by end of 2006.

The Company is encouraged by the scientific development of NEXVAS technology. The Company's science has progressed very quickly from a drug discovery stage of biotechnology research to proof-of-concept and is now in the process of lead selection for future toxicology testing. The hiring of world renowned experts and a dedicated staff has made a significant contribution to this rapid progression in meeting and exceeding corporate milestones.

The Company announced preclinical findings on its lead NEXVAS technology in October 2005. These research findings come from an expanding body of information illustrating the feasibility of small molecule ApoA1 enhancement in multiple animal models for the potential treatment of cardiovascular diseases and the regression of atherosclerosis. Resverlogix believes that with the consistency in animal models shown to date, its novel compounds illustrate properties likely to predict significant effects in humans as ApoA1/HDL raisers, eventually rendering them

effective products for treating CVD. The results of these experiments have contributed to the continued expansion and development of the *in vitro* and *in vivo* preclinical program.

Resverlogix recently announced that it had established a wholly-owned subsidiary called RVX Therapeutics Inc. (“RVX Therapeutics”) for business and strategic objectives. The parent company, Resverlogix Corp., will still hold its primary asset, NEXVAS ApoAI technology, for HDL applications focused on the dyslipidemia market. The purpose of RVX Therapeutics is to hold alternate technologies, such as the new discoveries for inflammation and DES markets as well the ongoing work on TGF- β Shield technology.

In July 2005, the Company announced exciting new research that could expand the NEXVAS commercial opportunity to acute coronary syndrome in addition to current focus on dyslipidemia (also referred to as the “chronic” market).

In August 2005, Resverlogix announced that on behalf of its wholly owned subsidiary, RVX Therapeutics, it has filed a patent application covering a unique and expanded application of its cardiovascular technology. The Company has discovered pharmaceutical compounds which have the potential to be used with medical devices such as drug-eluting stents. It is estimated that by 2010 the drug-eluting device market will generate revenues in excess of \$8.0 billion U.S. annually.

FINANCING ACTIVITIES

In June 2005, the Company announced a Normal Course Issuer Bid allowing the Company to repurchase up to 250,000 common shares during the period of June 24, 2005 to June 23, 2006 at the market price at the time of repurchase. All common shares repurchased by the Company will be cancelled. Pursuant to the Normal Course Issuer Bid, the Company has acquired 108,100 of its common shares at an average price of \$5.89 per share in the last six months. Total cost of this program including commissions has been \$646,857.

In the six months ended October 2005, the Company received \$21,744 from the exercise of 19,768 agent’s options issued at \$1.10 per share in connection with the 2003 Short Form Offering Document. The Company also received \$46,290 from the exercise of 37,032 agent’s options issued at \$1.25 and \$392,781 from the exercise of 130,927 agent’s options issued at \$3.00 per share to the agents in connection with various brokered private placements.

In the six months ended October 2005, the Company received \$980,330 in total from the exercise of 599,800 options varying in price from \$1.20 to \$2.25.

RESULTS OF OPERATIONS

Resverlogix incurred a net loss for the six months ended October 31, 2005 of \$3,465,831, or \$0.15 per share. The net loss for the six months ended October 31, 2004 was \$1,243,201 or \$0.07 per share. For the six months ended October 31, 2005, \$859,099 was recorded as the cost of stock based compensation as per the CICA guidelines as compared to \$36,137 for the same period of the prior year. Options awarded to key new employees as a recruitment and retention inducement and the first granting of options to the directors since their initial election to the Board in April 2003 resulted in the increase of this non-cash entry. The average monthly “burn rate”, revenues and expenditures excluding non-cash items, for the six months ended October 31, 2005 was \$415,000 as compared to \$190,000 for the same period in the prior year. The planned increase in cash expenditures is a result of continued acceleration of the scientific and business progression of the Company.

Revenue

The revenue of the Company consisted of interest earned on funds invested. Interest revenue was \$140,123 for the six months ended October 31, 2005, as compared to \$45,424 for the six months ended October 31, 2004.

Research and Development

For the six months ended October 31, 2005, research and development expenditures totaled \$1,788,072 with a recovery of \$5,203 for government grants through the National Research Council's IRAP program. For the six months ended October 31, 2004, research and development expenditures totaled \$603,072 with a recovery of \$47,219 for government grants. Key expense items relate to lead optimization of the Company's novel compounds. These expenses include chemical synthesis, pharmacokinetics studies and toxicology testing in preparation for IND application in the near future. Prominent contract research organizations and renowned academics were hired to expand and validate internal findings. Results are closely monitored for optimization while processes are in place to generate efficiencies in output per contracted employee. Internal expenses include salaries and benefits for R&D staff, consulting fees, supplies and general laboratory operating expenses. Expenses have increased steadily as additional staff members have been hired and the quantity and scope of experimentation have increased over the last year. The Company expects future research and development costs to increase in the next year when third-party pre-IND costs will be incurred.

General and Administrative

For the six months ended October 31, 2005, general and administrative expenditures totaled \$845,450, compared to \$628,728 for the six months ended October 31, 2004. General and administrative expenses includes salaries and other operating costs not directly involved in research and development, as well as professional fees for services, such as legal, audit, tax, investor relations and business development. The major expense for the six months ended October 31, 2005 was salaries, benefits and consulting fees for \$410,284. The Company also incurred \$127,903 for shareholder and IR expenses and \$121,431 for professional fees. The remaining expenditures were general operating costs.

SUMMARY OF QUARTERLY RESULTS

	For the three month period ended			
	Oct. 31 2005	July 31 2005	April 30 2005	Jan. 31 2005
Revenue	\$67,074	\$73,050	\$113,802	\$61,591
Net loss	(\$2,093,320)	(\$1,372,511)	(\$1,197,622)	(\$1,138,161)
Net loss per share (basic and fully diluted)	(\$0.09)	(\$0.06)	(\$0.05)	(\$0.05)

	For the three month period ended			
	Oct. 31 2004	July 31 2004	April 30 2004	Jan. 31 2004
Revenue	\$32,329	\$13,095	\$15,323	\$5,629
Net loss	(\$657,488)	(\$585,713)	(\$1,033,430)	(\$308,632)
Net loss per share (basic and fully diluted)	(\$0.04)	(\$0.03)	(\$0.06)	(\$0.02)

The increase in the quarterly losses is a result of the progression of the research and development activity of the Company and the timing of recording stock-based compensation expenses. In the quarter ended October 31, 2005, a stock-based compensation expense of \$662,737 was recorded. Also, in the fourth quarter of the 03/04 fiscal year (quarter ending April 30, 2004), a stock-based compensation expense of \$578,286 was recorded as the Company chose to early adopt the fair value method of accounting for options granted under its Stock Option Plan. The amortization of stock-based compensation is a non-cash expense.

LIQUIDITY

As at October 31, 2005, cash and near cash investments totaled \$10,204,758 as compared to \$12,103,450 at April 30, 2005. The Company's policy is to invest its cash reserves in low risk investments with a maturity of three months to two years at the time of purchase. The fixed income instrument maturity dates are usually matched to expected cash flow requirements. At October 31, 2005, the Company had working capital of \$9,792,922 compared to \$11,766,876 at April 30, 2005. Given the overall cash burn, the Company believes that it has sufficient cash reserves to operate for two years with the assumption of no revenues.

DISCLOSURE OF OUTSTANDING SHARE DATA (as at December 12, 2005)

Authorized and Issued Share Capital

Class	Par Value	Authorized	Issued
Common	No par value	Unlimited	24,003,969
Preferred	No par value	Unlimited	2,000,000 (Series A)

Description of Options, Warrants and Convertible securities outstanding

Security Type	Number	Exercise Price	Expiry Date
Options	948,700	\$1.60	4/25/08
Options	28,000	\$1.16	7/15/08
Options	75,000	\$1.20	9/5/08
Options	10,000	\$1.25	2/9/06
Options	200,000	\$1.50	3/15/08
Options	57,000	\$2.25	9/28/08
Options	200,000	\$2.25	9/28/09
Options	75,000	\$2.25	9/28/08
Options	30,000	\$4.50	2/16/09
Options	50,000	\$6.50	4/8/09
Options	20,000	\$7.00	5/6/09
Options	30,000	\$7.00	5/6/10
Options	25,000	\$5.50	6/27/10
Options	85,000	\$6.00	9/13/10
Options	60,000	\$6.00	9/13/07
Options	450,000	\$6.25	10/6/10
Agent's Options	40,586	\$1.25	2/20/06
Agent's Options	101,976	\$3.00	5/23/06
Total	2,486,262	\$1.16 to \$7.00	

RISKS AND UNCERTAINTIES

Resverlogix is at an early stage of development and has incurred losses to date. Developing new technologies will require further time and costs for research and development. It may be a number of years before the technology begins to generate revenues. There is no assurance that any of the Company's developments will be successful.

The success of Resverlogix is dependent on its ability to obtain patents and the proposed technology meeting acceptable cost and performance criteria in the marketplace. The Company will be dependent on ongoing marketing efforts in licensing of its technology.

ADDITIONAL INFORMATION

Additional information relating to the Company can also be found on SEDAR at www.sedar.com.

Notice to Reader

The management of Resverlogix Corp. is responsible for the preparation of the accompanying interim consolidated financial statements. The interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in Canada and are considered by management to present fairly the financial position, operating results and cash flows of the Company.

These interim financial statements have not been reviewed by an auditor. These interim consolidated financial statements are unaudited and include all adjustments, consisting of normal and recurring items, that management considers necessary for a fair presentation of the consolidated financial position, results of operations and cash flows.

Dated December 12, 2005.

signed "Donald J. McCaffrey"
President and CEO

signed "Hiran Perera"
CFO

RESVERLOGIX CORP.

Interim Consolidated Balance Sheets

	October 31, 2005	April 30, 2005
	(unaudited)	(audited)
Assets		
Current assets:		
Cash and cash equivalents	\$ 7,485,797	\$ 8,424,837
Marketable securities	2,718,961	3,678,613
Accounts receivable	–	79,473
Prepaid expenses	50,700	29,688
	<u>10,255,458</u>	<u>12,212,611</u>
Property and equipment (note 3)	792,480	545,412
Intellectual property and patents (note 4)	119,721	105,301
	<u>\$ 11,167,659</u>	<u>\$ 12,863,324</u>
Liabilities and Shareholders' Equity		
Current liabilities:		
Accounts payable and accrued liabilities	\$ 445,683	\$ 412,805
Current portion of equipment leases	16,853	32,930
	<u>462,536</u>	<u>445,735</u>
Shareholders' equity: (note 5)		
Common shares	19,489,927	17,619,707
Preferred shares	50,000	50,000
Contributed surplus	1,552,605	1,028,321
Warrants	173,317	351,367
Deficit	(10,560,726)	(6,631,806)
	<u>10,705,123</u>	<u>12,417,589</u>
Commitments (note 6)		
	<u>\$ 11,167,659</u>	<u>\$ 12,863,324</u>

See accompanying notes to the interim consolidated financial statements.

RESVERLOGIX CORP.

Interim Consolidated Statements of Operations and Deficit

	Three months ended October 31,		Six months ended October 31,	
	2005	2004	2005	2004
	(unaudited)		(unaudited)	
Revenue:				
Interest income	\$ 67,074	\$ 32,329	\$ 140,123	\$ 45,424
Expenses:				
Research and development	1,013,839	335,347	1,788,072	603,072
Research and development cost recoveries	–	(43,279)	(5,203)	(47,219)
General and administrative	425,086	327,329	845,450	628,728
Stock based compensation	662,737	36,137	859,099	36,137
Depreciation and amortization	62,711	34,283	108,973	67,907
Foreign exchange loss (gain)	(3,979)	–	9,563	–
	2,160,394	689,817	3,605,954	1,288,625
Loss for the period	2,093,320	657,488	3,465,831	1,243,201
Deficit, beginning of period	8,467,406	3,638,535	6,631,806	3,052,822
Share repurchase (note 5)	–	–	463,089	–
Deficit, end of period	\$10,560,726	\$ 4,296,023	\$10,560,726	\$ 4,296,023
Loss per common share – basic and diluted	\$ 0.09	\$ 0.04	\$ 0.15	\$ 0.07
Weighted average number of common shares	23,727,693	18,763,819	23,574,640	18,593,117

See accompanying notes to the interim consolidated financial statements.

RESVERLOGIX CORP.

Interim Consolidated Statements of Cash Flows

	Three months ended		Six months ended	
	October 31,		October 31,	
	2005	2004	2005	2004
	(unaudited)		(unaudited)	
Cash provided by (used in):				
Operations:				
Loss for the period	\$ (2,093,320)	\$ (657,488)	\$ (3,465,831)	\$ (1,243,201)
Items not involving cash:				
Depreciation and amortization	62,710	34,283	108,973	67,907
Stock based compensation	662,737	36,137	859,099	36,137
	(1,367,873)	(587,068)	(2,497,759)	(1,139,157)
Changes in non-cash working capital:				
Accounts receivable	21,405	(31,094)	79,473	(43,279)
Prepaid expenses	(8,826)	15,457	(21,012)	22,470
Accounts payable and accrued liabilities	7,501	(12,112)	32,878	76,299
	(1,347,793)	(614,817)	(2,406,420)	(1,083,667)
Financing:				
Issue of common shares for cash, net of costs	–	376,200	–	376,200
Proceeds from exercise of options and warrants	959,747	474,235	1,441,146	570,235
Share repurchase (note 5)	–	–	(546,879)	–
Equipment leases	(8,139)	(7,367)	(16,077)	(14,553)
	951,608	843,068	878,190	931,882
Investing:				
Marketable securities	283,630	(18,108)	959,651	463,828
Property and equipment additions	(131,153)	(27,493)	(352,634)	(49,261)
Patent additions	(13,351)	(59,490)	(17,827)	(70,435)
	139,126	(105,091)	589,190	344,132
Increase (decrease) in cash and cash equivalents	(257,059)	123,160	(939,040)	192,347
Cash and cash equivalents, beginning of period	7,742,856	345,634	8,424,837	276,447
Cash and cash equivalents, end of period	\$ 7,485,797	\$ 468,794	\$ 7,485,797	\$ 468,794

See accompanying notes to the Interim consolidated financial statements.

RESVERLOGIX CORP.

Notes to Interim Consolidated Financial Statements

As at October 31, 2005 and 2004

The interim consolidated financial statements of Resverlogix Corp. (the "Company") were prepared by management using accounting policies and methods of their application consistent with those used in the preparation of the Company's audited consolidated financial statements for the year ended April 30, 2005. The disclosure, which follows, is incremental to the disclosure included with the annual consolidated financial statements. These interim consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes thereto for the year ended April 30, 2005.

1. Nature of operations:

The Company is currently in the development stage and has no established commercial revenue and customer base.

The Company has the following projects under development:

(a) NEXVAS™:

The Company's lead technology NEXVAS™ is an ApoA1/high-density lipoprotein (HDL) enhancement program. ApoA1 is the key building block cardio protective protein of HDL (the good cholesterol). ApoA1/HDL enhancement technology focuses on the treatment of numerous cardiovascular diseases including the reversal of atherosclerotic plaque.

(b) TGF-β Shield™:

This technology is an approach to suppress the ability of cancers to avoid the immune system's cancer killing activity, and has been re-engineered to treat fibrotic diseases of the eye, liver, lung, heart and kidney. The initial technology was acquired in June 2003. In July 2004, the Company filed a patent application to protect the therapeutic applications of this technology.

Research and development expenditures on these projects are as follows:

	Three months ended		Six months ended		Cumulative since inception
	October 31,		October 31,		
	2005	2004	2005	2004	
NEXVAS	\$ 924,101	\$ 293,647	\$1,650,526	\$ 520,570	\$3,861,108
TGF-β Shield	89,738	41,700	137,546	82,502	451,163

As the Company has no established revenue base, it is reliant on equity financing for funding its projects under development. At October 31, 2005, the Company has \$9.8 million of working capital including \$10.2 million of cash and marketable securities. Management has concluded that it has sufficient working capital to fund its development and corporate operations beyond October 31, 2006.

RESVERLOGIX CORP.

Notes to Interim Consolidated Financial Statements, page 2

As at October 31, 2005 and 2004

2. Significant accounting policies:

Costs incurred in obtaining patents, all legal expenses to file, revise and defend patents, and all regulatory body fees relating to the patents are capitalized. Patent costs are amortized on a straight-line basis over the estimated life of the respective patents, being 18 years. On an ongoing basis, management reviews the valuation, taking into consideration circumstances which might have impaired the value.

3. Property and equipment:

October 31, 2005	Cost	Accumulated depreciation	Net book value
Laboratory equipment	\$ 780,867	\$ 240,297	\$ 540,570
Office furniture and equipment	43,617	20,294	23,323
Computer equipment	97,129	53,875	43,254
Computer software	23,055	13,313	9,742
Leasehold improvements	263,291	87,700	175,591
	<u>\$ 1,207,959</u>	<u>\$ 415,479</u>	<u>\$ 792,480</u>

April 30, 2005

Laboratory equipment	\$ 643,039	\$ 189,987	\$ 453,052
Office furniture and equipment	39,052	16,048	23,004
Computer equipment	81,760	39,633	42,127
Computer software	16,243	9,818	6,425
Leasehold improvements	75,231	54,427	20,804
	<u>\$ 855,325</u>	<u>\$ 309,913</u>	<u>\$ 545,412</u>

4. Intellectual property and patents:

October 31, 2005	Cost	Accumulated amortization	Net book value
Acquired property (NEXVAS)	\$ 818	\$ 68	\$ 750
Patents	128,504	9,533	118,971
	<u>\$ 129,322</u>	<u>\$ 9,601</u>	<u>\$ 119,721</u>

April 30, 2005

Acquired property (NEXVAS)	\$ 818	\$ 45	\$ 773
Patents	110,677	6,149	104,528
	<u>\$ 111,495</u>	<u>\$ 6,194</u>	<u>\$ 105,301</u>

RESVERLOGIX CORP.

Notes to Interim Consolidated Financial Statements, page 3

As at October 31, 2005 and 2004

5. Share capital:

(a) Issued and outstanding:

Common shares	Number of shares	Amount
Balance, April 30, 2004	18,382,415	\$ 5,197,767
Issued for cash in private placements	3,854,666	11,404,198
Issued on exercise of warrants	936,533	1,410,136
Issued on exercise of stock options	69,000	90,420
Transfer from warrants on exercise of warrants		714,145
Transfer from contributed surplus on exercise of options		64,830
Share issue costs		(1,261,789)
Balance, April 30, 2005	23,242,614	17,619,707
Issued on exercise of warrants	187,727	460,815
Issued on exercise of stock options	599,800	980,330
Transfer from warrants on exercise of warrants		178,050
Transfer from contributed surplus on exercise of options		334,815
Shares repurchased and cancelled	(93,100)	(83,790)
Balance, October 31, 2005	23,937,041	\$19,489,927

Series A Preferred shares	Number of shares	Amount
Balance, April 30, 2005	2,000,000	\$ 50,000
Balance, October 31, 2005	2,000,000	\$ 50,000

(b) Normal Course Issuer Bid:

On June 16, 2005, the Company announced a Normal Course Issuer Bid allowing the Company to repurchase up to 250,000 common shares during the period of June 24, 2005 to June 23, 2006 at the market price at the time of the repurchase. All common shares repurchased by the Company will be cancelled. Pursuant to the Normal Course Issuer Bid, the Company has acquired 93,100 of its common shares at an average price of \$5.79 per share. The excess of the purchase price over the stated capital of the common shares has been charged to the deficit.

RESVERLOGIX CORP.

Notes to Interim Consolidated Financial Statements, page 4

As at October 31, 2005 and 2004

5. Share capital (continued):

(c) Stock options:

The Company has a stock option program whereby the Company may grant options to its directors, officers, employees and consultants for up to 10% of the issued and outstanding common shares. The majority of options vest immediately and have a one to five year term.

	October 31, 2005		April 30, 2005	
	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
Outstanding at beginning of period	2,314,000	\$ 1.82	1,830,000	\$ 1.51
Granted	670,000	6.22	553,000	2.76
Exercised	(599,800)	1.63	(69,000)	1.31
Outstanding at end of period	2,384,200	\$ 3.10	2,314,000	\$ 1.82
Weighted average remaining contractual life	3.3 years		3.1 years	

The weighted average fair value of the options granted during the six months ending October 31, 2005 was \$3.77 per option using the Black-Scholes option pricing model with the following weighted average assumptions:

Risk free interest rate	4%
Expected life	2 to 5 years
Expected volatility (calculated once a year)	73%

RESVERLOGIX CORP.

Notes to Interim Consolidated Financial Statements, page 5

As at October 31, 2005 and 2004

5. Share capital (continued):

(d) Warrants:

The following table summarizes the changes in common share purchase warrants outstanding:

	Number of warrants	Amount	Weighted average exercise price
Outstanding, April 30, 2004	1,051,586	\$ 785,748	\$ 1.47
Granted in connection with private placement	256,664	279,764	3.00
Exercised during period	(936,533)	(714,145)	1.50
Outstanding, April 30, 2005	371,717	351,367	2.43
Exercised during period	(187,727)	(178,050)	3.00
Outstanding, October 31, 2005	183,990	\$ 173,317	\$ 2.41

The following table summarizes information about the common share purchase warrants outstanding and exercisable at October 31, 2005.

Outstanding	Exercise price	Expiry
61,886	\$ 1.25	February 20, 2006
122,104	\$ 3.00	May 23, 2006
183,990		

(e) Contributed surplus:

The changes in contributed surplus balance are as follows:

	Amount
Balance, April 30, 2004	\$ 582,650
Options exercised	(64,830)
Fair value of options granted	510,501
Balance, April 30, 2005	1,028,321
Options exercised	(334,815)
Fair value of options granted	859,099
Balance, October 31, 2005	\$ 1,552,605

RESVERLOGIX CORP.

Notes to Interim Consolidated Financial Statements, page 6

As at October 31, 2005 and 2004

5. Share capital (continued):

(f) Per share amounts:

The loss per share has been calculated based on the weighted average shares outstanding during the period. The effect upon the conversion of stock options and warrants is anti-dilutive.

6. Commitments:

As at October 31, 2005, the Company was committed to operating lease payments for office and laboratory premises as follows:

2006	\$	100,176
2007		100,176
2008		78,271
2009		43,637

The Company has an outstanding letter of credit for \$60,000 from a Canadian chartered bank. The letter of credit is secured by a short-term investment.

A special bonus is payable to directors, officers and employees conditional on the sale of the Nexvas technology on or before April 30, 2007. The special bonus is subject to final approval by the Board of Directors.

7. Financial instruments:

The fair value of monetary assets and liabilities, except the Company's marketable securities, approximate their carrying values, due to the short-term nature of these instruments. The market value of the marketable securities at October 31, 2005 was approximately \$2.7 million (April 30, 2005 - \$3.7 million).